Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Kymera Therapeutics (KYMR) Misses Q1 EPS by 5c
May 3, 2022 7:17 AM EDTKymera Therapeutics (NASDAQ: KYMR) reported Q1 EPS of ($0.71), $0.05 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $9.62 million versus the consensus estimate of $16.23 million.
For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.
... More